Background: Studies of long-term intake of industrially produced trans fatty acids (TFA) and n-3 polyunsaturated fatty acids (PUFA) suggest opposite effects on cardiovascular disease risk. Common mechanisms of action are probable. Objective: To examine the effects on cardiovascular risk markers of dietary enrichment with TFA or n-3 PUFA. Design: Randomized, double-blind, parallel intervention trial. Setting: Department of Human Nutrition, The Royal Veterinary and Agricultural University. Subjects: In all, 87 healthy males included, 79 completed. Intervention: Subjects were randomly assigned to 8 weeks of a daily intake of 33 g of experimental fats from either partially hydrogenated soy oil containing 20 g of TFA, 12 g of fish oil with approximately 4 g of n-3 PUFA and 21 g of control fat, or 33 g of control fat. The experimental fats were incorporated into bakery products. Plasma lipids, blood pressure, heart rate variability (HRV), arterial dilatory capacity, compliance, and distensibility were recorded before and after intervention and at follow-up 12 weeks after the intervention. Results: High-density lipoprotein cholesterol (HDL-C) decreased in the TFA group and triglycerides and mean arterial blood pressure decreased in the n-3 PUFA group compared to the control group. HRV, arterial dilatory capacity, compliance, and distensibility were unchanged.
Introduction
The apparently opposite effects on cardiovascular disease risk of foods rich in industrially produced trans fatty acids (TFA) and of n-3 polyunsaturated fatty acids (PUFA) from seafood have gained increasing attention. These opposing effects are seen, on the one hand, in the GISSI-Prevenzione trial where a reduction in total mortality and sudden cardiac death (SCD) was found in post-AMI patients supplemented with marine n-3 PUFA (Marchioli et al, 2002) , and in the Physicians' Health Study with a strong negative association between blood levels of long-chain n-3 PUFA and the risk of subsequent SCD (Albert et al, 2002) . Other studies have demonstrated a positive effect of n-3 PUFA on cardiovascular mortality (Burr et al, 1989; de Lorgeril et al, 1999; Valagussa et al, 1999) . Increased cardiovascular disease risk has on the other hand been found associated to TFA intake in epidemiological studies (Ascherio et al, 1996; Hu et al, 1997; Pietinen et al, 1997; Oomen et al, 2001; Lemaitre et al, 2002) .
Long-chained n-3 PUFA have been shown to have positive effects on blood lipids, haemostasis, leukocyte and vascular function, arterial compliance (AC) and heart rate variability (HRV) (Christensen et al, 1999; Goodfellow et al, 2000; Nestel et al, 2002) , the latter being a strong predictor of SCD (Curtis and O'Keefe Jr, 2002) . Industrially produced TFA adversely influence blood lipids (Ascherio et al, 1999) , as well as endothelial function (de Roos et al, 2001) . A recent casecontrol study indicates that TFA are associated to an enhanced risk of SCD (Lemaitre et al, 2002) . The mechanisms behind any attenuation or enhancement of the risk of SCD resulting from dietary intake of these fatty acids have, however, not been elucidated in detail. A modulation of membrane ion channel functions by altered fatty acid composition in cell membranes and/or in plasma could be such a mechanism (Patel et al, 2001; Katz, 2002) .
The above findings are presently being translated into public dietary recommendations aimed at increasing seafood intake (Kris-Etherton et al, 2002) and into regulations for labelling of foods with their content of industrially produced TFA (Stender et al, 1995; Wilkening, 2001; Food and Nutrition Board, 2002; Anonymous, 2002) . Denmark has as the first country introduced constraints on the use of industrially produced TFA in foods (Kristiansen et al, 2003) .
To our knowledge no dietary intervention study comparing the effects of marine n-3 PUFA and industrially produced TFA on cardiac risk markers has been performed. We thus found it pertinent to conduct a controlled dietary intervention trial with n-3 PUFA and industrially produced TFA with cardiac risk markers as primary end points.
Design, study participants and methods

Design
The study was a randomised, double-blind, parallel, 8 weeks dietary intervention trial, with a 12 weeks follow-up period. Study visits were at screening, at baseline, after 4 weeks of intervention, at the end of the intervention period, and at follow-up. The volunteers were screened 2-4 weeks prior to the start of the trial. The study participants were numbered consecutively and randomised to three intervention diets by drawing a sealed envelope with a coloured code. The diets were a TFA-enriched diet, a n-3 PUFA-enriched diet, and a control fat diet. All three diets included a daily intake of 33 g of experimental fats. The TFA fat was 33 g of partially hydrogenated soy oil containing 60% of TFA (Aarhus Olie, Aarhus, Denmark), providing 20 g of TFA daily. The n-3 PUFA group received 12 g of fish oil (EPAX 3000, Pronova Biocare, Aalesund, Norway) with approximately 4 g of n-3 PUFA, and 21 g of control fat. The participants in the control group were given 33 g of control fat with 60% saturated fatty acids (SFA) (Aarhus Olie, Aarhus, Denmark), equivalent to 20 g of SFA per day. Middle fractions of palm oil were used for the control fat. The fatty acid compositions of the experimental fats are given in Table 1 .
The experimental fats were incorporated into rolls and cakes, which were made at a professional bakery under the supervision of the kitchen staff of the Department. The products were packed and colour coded by the kitchen staff, stored at À201C, and given to the participants in frozen portions equivalent to 1 or 2 weeks' consumption.
The experimental foods consisted of a daily intake of two rolls and a piece of cake and replaced, isocalorically, the similar items in the participants' habitual diets. At the screening visit, the participants were instructed in the completion of a 4-day weighed food record, which was performed prior to the intervention, after 4 weeks, and at the end of the intervention. Energy intake and dietary analysis were conducted using a computerized programme, Dankost 2000, version 1.3 (Danish Catering Service, Herlev, Denmark) . Based on the food recordings, dietary counselling was given at baseline and after 4 weeks of intervention, to ensure that the energy intake was maintained at the participants' habitual levels during the intervention period. As the Dankost programme does not quantify the TFA content in the food, but includes TFA into saturated fat, the TFA intake in the habitual diet was arbitrarily set to 2,6 g/day, corresponding to the mean intake in Denmark (van Poppel, 1998) . This value was consequently subtracted from the calculated SFA content of the participants' diets. Also the quantification of n-3 PUFA intake is not specified in the Dankost programme. Information on average n-3 PUFA intake is not available to a degree that allows for a stipulation of the study participants habitual n-3 PUFA intake. Thus, the n-3 PUFA intake is included in the total PUFA intake estimation.
Study participants
In all, 93 male volunteers were recruited by public advertisements of which 87 qualified for enrolment (29 in each group). Inclusion criteria were: age 20-60 y, normal ECG and blood pressure, apparently healthy, and with no abnormalities in routine biochemical and haematological tests. A total of 79 participants completed the 8 weeks intervention period. One was excluded because of poor compliance; two left the study for private reasons, three because of difficulties in consuming the experimental diets, and two without explanation. Two persons were further lost at follow-up.
The sample size was chosen based on a power calculation enabling the detection of a variation in HRV of 10% at a 95% probability level, a b of 20%, and an estimated interindividual variation in RR equivalent to 80 ms. All participants were given oral and written information and signed an informed consent before enrolment. The protocol was approved by the Scientific Ethics Committee of the Municipalities of Copenhagen and Frederiksberg, Denmark, journal number (KF) 01-171/01.
The study groups were comparable with respect to demographic data, smoking, physical activity, and fish intake ( Table 2 ).
Methods
All examinations were performed after a minimum of 10 h of fasting at baseline, after the intervention period, and at follow-up.
Blood pressure (BP) was measured after a minimum of 10 min rest in the sitting position with a fully automatic blood pressure device (Omron M4-I, Hoofddorp, the Netherlands). An average of three recordings was used.
Blood samples were drawn after minimum 10 h of fasting. Routine haematological and biochemical analyses including blood lipids were performed. Platelets were isolated from whole blood, and platelet lipids were extracted, dissolved in heptane and transesterified with sodium methoxide and acetic acid. The content of fatty acids including TFA and n-3 PUFA was measured by gas chromotography on a Chrompack CP-9002 gas chromatograph (Varian BV, Middelburg, The Netherlands) with helium as the carrier gas, equipped with a CP-sil 88 column (Varian BV, Middelburg, The Netherlands). The results were expressed as per cent of total fatty acids.
A 24-h Holter recording was obtained in each participant using a two-channel tape recorder (Tracker Reynolds, Reynolds Medical, Hertford, UK). The tapes were analysed on a Reynolds Pathfinder 600 system (Reynolds Medical). All tapes were processed without knowledge of the randomization code. QRS complexes with abnormal morphology were excluded from the HRV analysis.
Flow-mediated dilation (FMD) and nitroglycerin-induced dilation (NID) of the brachial artery were examined as previously described (Clausen et al, 2001) . A 128XP/10 TM system (Acuson, USA) was used and all examinations were performed by the same technician and video-taped for later evaluation. The brachial artery was scanned in a longitudinal section just above the elbow, and arterial diameter was measured after at least 10 min of supine rest (I). The measurement was then repeated after inflation of a tourniquet on the forearm to a pressure of 300 mmHg for 4.5 min immediately before release (II), 50-60 s after tourniquet release (III), at least 10 min after tourniquet release to allow for vessel recovery (IV), and finally 3-4 min after sublingual administration of 400 mg nitroglycerin (V). The mean diameter for each measurement was calculated by two observers blinded to subject characteristics and the sequence of the scan protocol, from four cardiac cycles incident with the R wave, on a simultaneously recorded ECG. The mean values for arterial diameters, calculated by the two observers, were expressed as percentage of the resting scan diameter, diameter III/diameter I (FMD) and diameter V/diameter I (NID), respectively. The intraindividual coefficients of variation for FMD and NID were 3.6 and 3.9%, respectively, based on nine scans of the same subject performed on separate days within 2 weeks (Clausen et al, 2001) . The arterial compliance (AC) and distensibility (AD) controlled for the transmural pressure (TMP) were measured, after 15 min rest in the supine position, in the arm and the leg,by a volume-oscillometric method (Wiinberg, 2000) , using an Artcomp s from Criticon, Tampa, USA. Volume changes were measured during a 10 mmHg stepwise deflation of an occlusive cuff placed on the limb from suprasystolic pressure to 50 mmHg. The volume and pulse pressure changes were obtained in a range of TMP from approximately À60 mmHg to þ 60 mmHg. The arterial compliance at different TMP was calculated from the volume changes (AV) and changes in the simultaneously recorded blood pressure, where AC ¼ DV/DP, P ¼ pulse pressure. The absolute volume (AV) of the artery underlying the 10 cm wide cuff was calculated from the AC and the measured TMP as AV ¼ R (DV/ DP) DTMP. The distensibility was obtained by dividing the AC with the AV at the same TMP: AD ¼ AC/AV ¼ (DV/DP)/AV. Four recordings were performed on the left arm and three on the left leg.
Statistical analysis
Comparisons between the controls and the TFA group or the n-3 PUFA group were tested by an unpaired t-test. Differences in nominal data were evaluated by the w 2 test. A P-value o0.05 (two-tailed) was considered statistically significant. To test for within group differences a paired t-test was used. All analyses were performed using SPSS software version 10.0 (SPSS Inc., Chicago, IL, USA).
Results
Intervention diets
The body weight and composition of the diets at baseline and at the end of the intervention period are given in Table 3 . Total energy consumption and body weight were unchanged during the intervention. The intervention diets resulted in an increase of approx. 5E% in total fat consumption in all groups. An increase in TFA intake of 6 E% from the experimental diet was obtained in the TFA group, and a similar increase was found in the SFA intake in the control group. In the n-3 PUFA group the 4 E% (12 g) fish oil, resulted in a significantly lower SFA intake compared to the control group. The other differences between the three groups were of minor magnitude.
The fatty acid pattern in platelet membranes is given in Table 4 . The changes indicate a good compliance to the intervention diets. Only a minor, though significant, increase in the TFA group was observed in trans-18:2. In the n-3 PUFA group the rise in n-3 PUFA was accompanied by a fall in total n-6 PUFA, whereas the TFA increment in the TFA group corresponds to a fall in both saturated and cismonounsaturated fatty acids. At the 12 weeks follow-up the fatty acid patterns were almost reverted to baseline levels in all groups.
Blood pressure A minor fall was observed in the n-3 PUFA group in mean arterial pressure (MAP) significantly different from the control group (Po 0.05) ( Table 5 ).
Plasma lipids and lipoproteins
A fall in HDL-C in the TFA group and in triglycerides in the n-3 PUFA group was significantly different from the control group (Table 6 ).
The alterations in plasma lipids in the TFA and n-3 PUFA groups were still present at follow-up. The lipid changes in the control group all reverted to baseline levels at follow-up, except for HDL-C, which fell below baseline level.
Heart rate variability (HRV)
A complete set (baseline, after 8 weeks of dietary intervention, and follow-up) of successful 24 h Holter monitorings was obtained in 76 of the 79 subjects completing the trial.
As seen from Table 7 there was no overall effect of the intervention diets on HRV-indices when compared to the control group. SDANN decreased significantly in the n-3 PUFA group compared to controls.
A post hoc analysis, dividing the results according to SDNN quartiles at baseline, and excluding the men belonging to the upper quartile with extremely high HRV (n ¼ 19, mean SDNN 235 ms), gave some interesting indications. This left a group of men with a normal SDNN (n ¼ 35, mean SDNN 156 ms) at baseline. A decrease on 31 and 5 ms, respectively, was observed in RR and RMSSD in the TFA group, this fall being significantly different from the controls and the n-3 PUFA group.
Arterial dilatory capacity A complete set (baseline, after 8 weeks of dietary intervention and follow-up) of successful FMD and NID scans was obtained in 75 and 76, respectively, of the 79 subjects completing the trial. The results are given in Table 8 . There was no effect of the intervention on either FMD or NID in any groups compared to the control group.
Arterial compliance and distensibility A set of AC and AD measurements at baseline and after 8 weeks of intervention was obtained on the arm in 76 and on the leg in 73 of 79 subjects. There was no effect at a transmural pressure of 100 mmHg of 8 weeks of dietary (24) 877 (25) 849 (21) 863 (20) 876 (26) 888 (28) SDNN (ms) 177 (8) 191 (9) 173 (10) 170 (8) 177 (10) 190 (11) SDNNi (ms) 84 (6) 82 (6) 77 (6) 74 (5) 78 (5) 81 (7) SDANN (ms) 156 (8) 171 (7) 156 (9) 149 (7)z 157 (10) 173 (9) RMSSD (ms) 52 (5) 49 (4) 49 (7) 46 (5) 46 (5) Values are mean (s.e.m.). Mean difference significantly different from mean difference of control group: zPo0.05. Abbreviations: RR, mean of all normal RR intervals during the 24-h recording; SDNN, standard deviation of all normal RR intervals in the entire 24-h recording; SDNN index, mean of the standard deviations of all normal RR intervals for all 5-min segments of the 24 recordings; SDANN index, standard deviation of the mean RR intervals measured in successive 5-min periods; RMSSD, square root of the mean sum of the squares of differences between adjacent intervals; NN50 count, total number of successive RR-interval differences Z50 ms; NN6% count, total number of successive RR-interval differences Z6%. Table 8 Flow-mediated dilation (FMD) and nitroglycerin-induced dilation (NID) of the brachial artery in the study groups at baseline, after 8 weeks of intervention and at follow-up intervention in any of the groups in either the arm or the leg (data not shown).
Discussion
The present study is, to our knowledge, the most comprehensive dietary intervention study yet conducted, comparing the effects of n-s PUFA and industrially produced TFA on functional cardiovascular risk markers. One of the main aims of the study was to investigate whether TFA in the diet influences cardiovascular risk markers in a way that could add to the understanding of the discrepancy between the moderate risk increment caused by TFA on blood lipid levels (Ascherio et al, 1999) and the observed substantial risk found in prospective epidemiological studies (Oomen et al, 2001 ). In the Ascherio et al (1999) meta-analysis of the effect of TFA on blood lipids, 2 E% TFA was found to influence these in a magnitude corresponding to an increased CHD risk of 5%. In a meta-analysis of four prospective epidemiological studies Oomen et al (2001) found that a 25% risk increment for CHD was associated to an intake of 2 E% TFA. Effects of TFA on risk markers other than blood lipids thus seem plausible, even if a new study indicates that TFA also can influence LDL particle size (Mauger et al, 2003) . It is in that respect noteworthy that the Lemaitre et al (2002) case-control study indicated an association between TFA intake and SCD. n-3 PUFA contrastingly decrease the risk of SCD (Valagussa et al, 1999; Albert et al, 2002) . These effects could be due to changes in membrane fatty acid composition in cardiac conductory or contractile cells (Patel et al, 2001; Katz, 2002) . As the fatty acid turnover rate in these cells is unknown, a rather long dietary intervention period of 8 weeks was chosen in the study.
The effects of the TFA diet on blood lipids in the present study were in line with those found in the Ascherio et al (1999) meta-analysis however, rather modest. This further emphasizes the need for investigating other mechanisms of action of these food components on CHD risk. The effects of the n-3 PUFA diet on HDL-C and triglycerides were parallel to results from the majority of other studies (Harris, 1997) .
We found no effect of the TFA diet on BP, which is in line with the results of other studies (Mensink et al, 1991) . Mean arterial blood pressure decreased modestly in the n-3 PUFA group. This corresponds to the findings in other studies on fish oil supplementation.
In a study of dyslipidaemic subjects, supplemented with fish oil in a dose and in an intervention period comparable to the present, Nestel et al (2002) found a significant improvement of the systemic arterial compliance, which is a measure of the function of predominantly large elastic arteries. In the present study, arterial compliance was measured regionally, in predominantly medium-sized muscular arteries, without effect in either the TFA or the n-3 PUFA study group. The reason for this discrepancy is not obvious, but could be due to a different situation in dyslipidaemic subjects compared to healthy volunteers, but it may also be due to the central arteries responding differently to fatty acids than peripheral arteries.
We found no effect of 8 weeks dietary enrichment with either TFA or n-3 PUFA on endothelial function, measured as flow-mediated vasodilatation. This is in contrast to the findings by de Roos et al (2001) , who found a significant fall in FMD after a TFA diet compared to a SFA diet in a 4-week crossover intervention trial with 9.2 E% TFA and SFA. This discrepancy could be an effect of the 50% larger TFA dose and the 21% reduction in HDL found in this study. The TFA dose in the present study (6.0 E%) is, however, substantially above the 2 E% to which a 25% associated increased risk for CHD was found in epidemiological studies (Oomen et al, 2001) . This indicates that the effect of TFA on FMD is of minor importance for the above risk associations. We were unable to confirm an effect of fish oil on arterial endothelial function, which has been found previously in a few studies in hypercholesterolaemic and heart transplant patients (Goodfellow et al, 2000) . This could be due to the use of healthy volunteers in the present study, and that the earlier studies used patients given fish oil supplementation to the diets, whereas the healthy men in the present study received a saturated fat diet in combination with n-3 PUFA.
As was the case with FMD, we found no overall effect of the dietary interventions on HRV. The study population consisted of healthy men with a habitual high HRV. A positive effect on HRV was observed in all groups, possibly due to increased attention to physical health during the study period. However, also at baseline our group of healthy men showed a very high HRV compared to other studies of normal men (Kleiger et al, 1991) . It is therefore of interest that in the subgroup analysis, after excluding the 25% of the men with the highest HRV at baseline and leaving the men with a mean SDNN of 156 ms, a value which is comparable to previous reported SDNN data for normal men (Kleiger et al, 1991) , an increase in 24-h heart rate ( ¼ decreased RR) was found in the TFA group contrasting to an increase in RR in the other groups. The increase in heart rate in the TFA group corresponds to approximately 3 bpm. A high heart rate is associated with an increased cardiovascular mortality (Kannel et al, 1987; Greenland et al, 1999; Reunanen et al, 2000) . Furthermore, HRV indices associated with vagal cardiac modulation (RMSSD, pNN50, pNN6%) (Camm et al, 1996) were attenuated, although not significantly, after dietary supplementation with TFA. This is important, because autonomic dysfunction with a decreased vagal activity is closely related to SCD. Thus, our results give some support to the finding that the risk of SCD is associated to TFA intake, as in the case-control study by Lemaitre et al (2002) however only to trans 18:2.
Previous studies have shown a beneficial effect of n-3 fatty acids on HRV in different populations (Christensen et al, 1999 (Christensen et al, , 2001a . As in another study with healthy men (Christensen et al, 1999) , we observed an increase in HRV in the analysis of men with the lowest SDNN when supplemented with n-3 PUFA.
In conclusion, this dietary intervention study demonstrates only a minor divergence in the effect on a number of risk markers for CHD including plasma lipids, function of the arterial wall, and conductivity in the heart in healthy males by 8 weeks dietary intervention with TFA and n-3 PUFA corresponding to approximately 6 and 1.2 E%, respectively. Our results, however, emphasize the need for further studies aimed at elucidating the mechanisms behind the association between the fatty acid composition of the diet and the risk of CHD. In particular, any additional effects of TFA, besides the modulation of plasma lipids, whether industrially produced or of ruminant origin, are of major interest. Our findings may suggest that industrially produced, predominantly monoenoic TFA increase heart rate in healthy volunteers. These results call for further studies testing specific trans fatty acids in cardiovascular risk groups.
